Actinium Pharmaceuticals announced new data presentations for its ATNM-400 targeted radiotherapy at the SNMMI 2026 Annual Meeting, highlighting its potential in prostate and non-small cell lung cancers. The company also disclosed a notice from NYSE American about non-compliance with listing standards due to low stockholders' equity and ongoing losses, requiring a compliance plan by June 26, 2026. Despite this, Actinium plans to continue trading and aims to regain compliance by November 2027. Upcoming catalysts for its pipeline therapies are expected in the second half of 2026, signaling ongoing development progress.
YieldMax announced it will close and liquidate four ETFs—ABNY, DISO, FEAT, and FIVY—by June 18, 2026, following a portfolio review. The decision aims to concentrate resources on ETFs with higher investor demand and better market traction. Trading for...
Canborsa has launched the beta version of its decentralized exchange (DEX) on the Canton Network, enabling non-custodial perpetual trading of tokenized real-world assets like stocks, gold, oil, and cryptocurrencies with up to 20x leverage. The platfo...
Oculis announced that its Phase 3 DIAMOND trials for OCS-01 eye drops in diabetic macular edema did not meet the primary endpoint of improved visual acuity after 52 weeks. However, the treatment showed significant and lasting reduction in retinal thi...
Allied Gold Corporation announced that Zijin Gold has received approval under the Investment Canada Act for its proposed acquisition of Allied Gold. This approval completes the Canadian regulatory process for the transaction. The deal has also cleare...
Kentucky First Federal Bancorp announced a special board meeting on July 28, 2026, to consider resuming quarterly dividends on its common stock, potentially up to $0.10 per share. The company has suspended dividends since November 2023, and no final ...
